ArticleLeukemia2014
APOBEC3 signature mutations in chronic lymphocytic leukemia.
Article in Leukemia, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells.European journal of immunology · 2014Trial
- scHiClassifier: a deep learning framework for cell type prediction by fusing multiple feature sets from single-cell Hi-C data.Briefings in bioinformatics · 2024Article
- Active DNA demethylation-The epigenetic gatekeeper of development, immunity, and cancer.Advanced genetics (Hoboken, N.J.) · 2021Review
- Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes.Frontiers in cell and developmental biology · 2021Article
- Alternative splicing of APOBEC3D generates functional diversity and its role as a DNA mutator.International journal of hematology · 2020Article
- Article
- A practical guide for mutational signature analysis in hematological malignancies.Nature communications · 2019Article
- APOBEC3B up-regulation independently predicts ovarian cancer prognosis: a cohort study.Cancer cell international · 2018Article
- Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.British journal of cancer · 2017Article
- Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.Cell communication and signaling : CCS · 2017Review
- APOBEC3B expression in human leptomeninges and meningiomas.Oncology letters · 2016Article
- Whole-genome sequencing reveals activation-induced cytidine deaminase signatures during indolent chronic lymphocytic leukaemia evolution.Nature communications · 2015Article
- Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif.Oncotarget · 2015Article
- APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.Cancer discovery · 2015Review
- AID/APOBEC deaminases and cancer.Oncoscience · 2015Review
- Clusters of Multiple Mutations: Incidence and Molecular Mechanisms.Annual review of genetics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.